Herantis Pharma Plc (Finland)
Herantis Pharma is a biopharmaceutical company developing novel therapies for unmet medical needs. Herantis was founded in 2008 as a University of Helsinki spin-off company, and is an SME organisation according to EU definitions. Herantis aims to develop novel pharmaceutical products based on some of the leading scientific research in the world. Herantis’ focus is in indications with unmet clinical needs such as disease-modifying treatments in Parkinson’s.
Herantis’ strategy is to bridge the gap between academic research and commercial late-stage drug development through its expertise in late preclinical and early clinical development, aiming to reach a clinical proof-of-concept and then find larger pharmaceutical companies as partners for late-stage clinical development.
Renishaw Plc (United Kingdom)
Renishaw is one of the world’s leading engineering and scientific technology companies, with expertise in precision measurement and healthcare. In its line of neurological products, the company applies precision engineering technology to the challenges of functional neurosurgery, with commercial products like the neuromate® stereotactic robot, the neuroinspire™ surgical planning software, and the neuroguide™ DBS electrode delivery system. The Drug Delivery System (DDS), currently in development, is intended for intracerebral drug delivery, and will complement the existing product portfolio of the company.
The expertise of Renishaw Plc in commercialising neurosurgical products, combined with its existing international delivery and support organisation, can be directly utilised for benefit of the TreatER project.
Karolinska University Hospital (KUH) (Sweden)
Karolinska University Hospital is one of Scandinavia’s premier healthcare facilities and one of the largest university hospitals in Europe, with over 1.6 million patient visits and over 50.000 foreign patients. Together with the world-respected Karolinska Institutet, KUH leads in breakthroughs in many fields of medicine. KUH combines patient care with research, innovation and education, with their vision “Patient first.”
Specific to clinical trials, KUH has the Karolinska Trial Alliance (KTA), a clinical research unit located in Stockholm. The Phase 1 unit of KTA conducts clinical trials for the pharmaceutical/medical appliance industry and for academic researchers. KTA cooperates with the departments of the entire Karolinska University Hospital and also with the Karolinska Institutet. This gives it access to the extensive resources of one of Europe’s leading university hospitals in relation to early clinical trials, including a radiology department and laboratory as well as the Karolinska Institute’s world-leading researchers. The Phase 1 Unit has 16 beds and experienced GCP-trained personnel to carry out clinical studies from first-in-human to proof-of-concept.
Skåne University Hospital (Sweden)
Skåne University Hospital is the third largest of Sweden’s seven university hospitals and is a part of Region Skåne. The three cornerstones of the hospital are advanced medical care, training and prominent research. Their training and research aim to benefit future patients while also being of great importance for social development and economic life. 1.7 million people throughout southern Sweden are able to benefit directly from the highly specialised care at the Skåne University Hospital.
The Department of Neurology of Skåne University Hospital is one of the departments conducting clinical studies in Lund, Sweden. The focus is in the most common neurological diseases: stroke, epilepsy and Parkinson’s disease as well as other movement disorders. The Department of Neurology drives research through close collaboration with clinical and non-clinical researchers. The close coupling of the hospital with the medical faculty of Lund University has had a major impact in advancing neurological research and clinical development. Lund University is of unique importance in the field of Parkinson’s research, starting with Professor Arvid Carlsson’s Nobel-awarded work on the discovery of dopamine in the 1950’s. More recent examples of pioneering research include brain cell transplants as a regenerative therapy in Parkinson’s.
Helsinki University Hospital (HUS) (Finland)
Helsinki University Hospital is the largest of the five university hospital districts in Finland. HUS employs nearly 21,000 healthcare professionals to offer high-quality specialist medical care in all of its hospitals in Helsinki and throughout the province of Uusimaa. All of the major medical specialties are represented at HUS, including neurology and neurosurgery. The work of HUS also includes medical and other health science research. The medical research and teaching centre Biomedicum, where the university teaching in basic and specialised medicine, and the international research teams are centralised, is owned by HUS and the University of Helsinki.
In the HUS area, all neurosurgical operations are performed at the Department of Neurosurgery at Töölö Hospital. The Department of Neurosurgery is the oldest neurosurgical department in Finland, established in 1932, and today the largest in Finland. It serves the whole southern Finland area with a population of nearly 2 million and is world-famous for its expertise in all subsections of neurosurgery. Each year, more than 3,200 patients undergo neurosurgical treatment at the Department of Neurosurgery at HUS.
Karolinska Institutet (Sweden)
The Karolinska Institutet is one of the world’s foremost medical universities and Sweden’s single largest centre of medical academic research offering the country’s widest range of medical courses and programmes. The vision of KI is to make a significant contribution to the improvement of human health; its mission is to conduct research and education and to interact with the community.
Since 1901 the Nobel Assembly at the Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.
Specific to Parkinson’s, the PET Centre at the Karolinska Institutet has developed novel methods of utilising PET imaging in people with Parkinson’s, and applied the results of this research in clinical development.
University of Helsinki (Finland)
The University of Helsinki is one of the top multidisciplinary Nordic universities. Established in 1640, the University of Helsinki is the biggest university in Finland with 11 faculties, several research institutes and more than 7,000 staff and 32,000 students. In international university rankings, the University of Helsinki typically ranks among the top 100. The University of Helsinki is a member of the League of European Research Universities (LERU), an association of 21 leading European universities promoting the conditions and opportunities for basic research in Europe.
University of Oxford (United Kingdom)
The University of Oxford is the oldest university in the English-speaking world and is continuously a global leader. The University of Oxford is especially praised for its research. Neuroscience in particular has been ranked world-leading according to the Research Excellence Framework.
Specific to Parkinson’s disease, the University of Oxford has a unique multidisciplinary research centre, the Oxford Parkinson’s Disease Centre (OPDC). Established in 2010, the OPDC brings together internationally renowned scientists covering, for example disease genetics, cell and animal models, and clinical expertise in diagnosis and treatments. The Oxford brain bank is one of the most well characterised Parkinson’s brain banks in the world.
The European Parkinson’s Disease Association (EPDA) is the only European Parkinson’s umbrella organisation. It has been championing and working with the global Parkinson’s community for 25 years. As the leading voice for Parkinson’s in Europe, the EPDA provides information and resources to all Parkinson’s stakeholders, raising awareness of the disease’s complexities and impact, and advocating for concrete policy change that benefits the Parkinson’s community.
EPDA’s vision is to enable all people with Parkinson’s to live a full life, while supporting the search for a cure. To this end, its core activities are to:
The EPDA engages and connects with the Parkinson’s community across Europe and the globe to champion collaborations and partnerships, helps develop solutions to unmet needs, and raises awareness of the impact of the disease with decision makers.
Through its online library – the biggest in Europe – the EPDA provides up-to-date information, research and resources for Parkinson’s stakeholders to educate, advise and share good practices.
The EPDA represents national Parkinson’s associations – that collectively have more than 120,000 members in nearly 30 countries across Europe – and advocates for the rights and needs of more than 1.2 million people with Parkinson’s and their families.
The EPDA provides an authoritative voice on the impact of Parkinson’s across Europe and advocates for policy change that benefits the European Parkinson’s community.
Orion Pharma (Finland)
Orion Pharma is a globally operating developer of pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. It is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical research and development are central nervous system disorders, oncology and respiratory.
Orion’s customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Orion’s products are marketed in over a hundred countries, and the Group’s own human pharmaceuticals sales organisation covers almost all key European markets.
Development of drugs for the treatment of Parkinson’s disease has long been in the very core of Orion Pharma’s strategy and its greatest international commercial successes include Parkinson’s.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such Parkinson’s disease, which is one of the four main target indications of the company’s research and development efforts.
Focus on research and development is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. The company cooperates closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions.